Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy

Published:2018-08 Issue: Volume:128 Page:110-117
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Zhao Bin,Zhao Hong,Zhao Jiaxin

Funder

National Natural Science Foundation of China

Natural Science Foundation of Heilongjiang Province

Health and Family Planning Commission Foundation of Heilongjiang Province

Start-up Foundation of Harbin Medical University

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference54 articles.

1. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP foundation study FB-9;Abraham;Breast Cancer Res. Treat.,2015

2. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial;Aftimos;Eur. J. Cancer,2016

3. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer;Aogi;Ann. Oncol.,2012

4. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest oncology group trial S0618;Arnold;Invest. New Drugs,2011

5. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer;Ates;J. Buon,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study;Breast Cancer Research;2022-10-28

2. Clinical and preclinical features of eribulin-related peripheral neuropathy;Experimental Neurology;2022-02

3. Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity;Journal of Medicinal Chemistry;2021-10-14

4. Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient;Internal Medicine;2021-08-15

5. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3